1. Home
  2. MREO vs ALT Comparison

MREO vs ALT Comparison

Compare MREO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • ALT
  • Stock Information
  • Founded
  • MREO 2015
  • ALT 1997
  • Country
  • MREO United Kingdom
  • ALT United States
  • Employees
  • MREO N/A
  • ALT N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • MREO Health Care
  • ALT Health Care
  • Exchange
  • MREO Nasdaq
  • ALT Nasdaq
  • Market Cap
  • MREO 438.8M
  • ALT 397.4M
  • IPO Year
  • MREO N/A
  • ALT N/A
  • Fundamental
  • Price
  • MREO $1.66
  • ALT $4.19
  • Analyst Decision
  • MREO Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • MREO 5
  • ALT 6
  • Target Price
  • MREO $7.20
  • ALT $18.20
  • AVG Volume (30 Days)
  • MREO 3.5M
  • ALT 11.7M
  • Earning Date
  • MREO 08-12-2025
  • ALT 08-07-2025
  • Dividend Yield
  • MREO N/A
  • ALT N/A
  • EPS Growth
  • MREO N/A
  • ALT N/A
  • EPS
  • MREO N/A
  • ALT N/A
  • Revenue
  • MREO N/A
  • ALT $20,000.00
  • Revenue This Year
  • MREO N/A
  • ALT N/A
  • Revenue Next Year
  • MREO $52.34
  • ALT $1,557,547.90
  • P/E Ratio
  • MREO N/A
  • ALT N/A
  • Revenue Growth
  • MREO N/A
  • ALT N/A
  • 52 Week Low
  • MREO $1.58
  • ALT $2.90
  • 52 Week High
  • MREO $5.02
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • MREO 29.70
  • ALT 39.67
  • Support Level
  • MREO $2.77
  • ALT $4.33
  • Resistance Level
  • MREO $3.05
  • ALT $4.79
  • Average True Range (ATR)
  • MREO 0.18
  • ALT 0.52
  • MACD
  • MREO -0.06
  • ALT -0.16
  • Stochastic Oscillator
  • MREO 9.76
  • ALT 26.92

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: